Postprandial prolactin suppression appears absent in antipsychotic-treated male patients

Research output: Contribution to journalLetterResearchpeer-review

Standard

Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. / Coello, Klara; Broberg, Brian V; Bak, Nikolaj; Madsen, Anna; Mortensen, Henrik B; Søgaard, Birgitte; Szecsi, Pal B; Knop, Filip K; Lublin, Henrik; Ebdrup, Bjørn H.

In: Psychoneuroendocrinology, Vol. 60, 10.2015, p. 1-6.

Research output: Contribution to journalLetterResearchpeer-review

Harvard

Coello, K, Broberg, BV, Bak, N, Madsen, A, Mortensen, HB, Søgaard, B, Szecsi, PB, Knop, FK, Lublin, H & Ebdrup, BH 2015, 'Postprandial prolactin suppression appears absent in antipsychotic-treated male patients', Psychoneuroendocrinology, vol. 60, pp. 1-6. https://doi.org/10.1016/j.psyneuen.2015.05.014

APA

Coello, K., Broberg, B. V., Bak, N., Madsen, A., Mortensen, H. B., Søgaard, B., Szecsi, P. B., Knop, F. K., Lublin, H., & Ebdrup, B. H. (2015). Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. Psychoneuroendocrinology, 60, 1-6. https://doi.org/10.1016/j.psyneuen.2015.05.014

Vancouver

Coello K, Broberg BV, Bak N, Madsen A, Mortensen HB, Søgaard B et al. Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. Psychoneuroendocrinology. 2015 Oct;60:1-6. https://doi.org/10.1016/j.psyneuen.2015.05.014

Author

Coello, Klara ; Broberg, Brian V ; Bak, Nikolaj ; Madsen, Anna ; Mortensen, Henrik B ; Søgaard, Birgitte ; Szecsi, Pal B ; Knop, Filip K ; Lublin, Henrik ; Ebdrup, Bjørn H. / Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. In: Psychoneuroendocrinology. 2015 ; Vol. 60. pp. 1-6.

Bibtex

@article{36e435ee61a14d7183b4a89575a23660,
title = "Postprandial prolactin suppression appears absent in antipsychotic-treated male patients",
abstract = "INTRODUCTION: Hyperprolactinemia is a common side-effect of antipsychotic treatment. Antipsychotics and hyperprolactinemia are both considered risk factors of metabolic disturbances and diabetes. Investigations on prolactin response to meal ingestion in antipsychotic-treated patients are missing.MATERIAL AND METHODS: In a case-control design, 49 antipsychotic-treated, clinically stable, non-diabetic, schizophrenia spectrum male patients were compared with 93 healthy male controls by age (33.1, SD 7.4 vs. 32.9, SD 6.6 years), body mass index (26.2, SD 4.6 vs. 26.1, SD 3.9 kg/m(2)) and waist circumference (96.4, SD 13.0 vs. 96.7, SD 11.9 cm). Serum-prolactin was measured in the morning and 90 min after ingestion of a standardized liquid meal (2268 kJ).RESULTS: Fasting prolactin levels varied considerably, and mean fasting prolactin levels did not significantly differ between patients and controls (12.33, SD 11.58 vs. 10.06, SD 8.67 ng/ml, p = 0.623). In the controls, postprandial serum prolactin was significantly reduced (Δ -2.53, SD 9.75 ng/ml, p = 0.016). In antipsychotic-treated patients postprandial serum prolactin tended to increase (Δ 2.62, SD 10.96 ng/ml, p = 0.081). Analyses of subgroups based on the prolactinogenic liability of their antipsychotic treatment indicated 22 to 65% higher postprandial prolactin levels with high and intermediate prolactinogenic antipsychotics.DISCUSSION: A physiological postprandial suppression of serum prolactin appears absent in antipsychotic-treated males. Marked variability in fasting prolactin levels may reflect individual variations in the diurnal cycle. Uniform acquisition procedures accounting for diurnal variation and food intake may enhance reliability of prolactin levels in antipsychotic-treated male patients.",
author = "Klara Coello and Broberg, {Brian V} and Nikolaj Bak and Anna Madsen and Mortensen, {Henrik B} and Birgitte S{\o}gaard and Szecsi, {Pal B} and Knop, {Filip K} and Henrik Lublin and Ebdrup, {Bj{\o}rn H}",
note = "Copyright {\textcopyright} 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2015",
month = oct,
doi = "10.1016/j.psyneuen.2015.05.014",
language = "English",
volume = "60",
pages = "1--6",
journal = "Psychoneuroendocrinology",
issn = "0306-4530",
publisher = "Pergamon Press",

}

RIS

TY - JOUR

T1 - Postprandial prolactin suppression appears absent in antipsychotic-treated male patients

AU - Coello, Klara

AU - Broberg, Brian V

AU - Bak, Nikolaj

AU - Madsen, Anna

AU - Mortensen, Henrik B

AU - Søgaard, Birgitte

AU - Szecsi, Pal B

AU - Knop, Filip K

AU - Lublin, Henrik

AU - Ebdrup, Bjørn H

N1 - Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2015/10

Y1 - 2015/10

N2 - INTRODUCTION: Hyperprolactinemia is a common side-effect of antipsychotic treatment. Antipsychotics and hyperprolactinemia are both considered risk factors of metabolic disturbances and diabetes. Investigations on prolactin response to meal ingestion in antipsychotic-treated patients are missing.MATERIAL AND METHODS: In a case-control design, 49 antipsychotic-treated, clinically stable, non-diabetic, schizophrenia spectrum male patients were compared with 93 healthy male controls by age (33.1, SD 7.4 vs. 32.9, SD 6.6 years), body mass index (26.2, SD 4.6 vs. 26.1, SD 3.9 kg/m(2)) and waist circumference (96.4, SD 13.0 vs. 96.7, SD 11.9 cm). Serum-prolactin was measured in the morning and 90 min after ingestion of a standardized liquid meal (2268 kJ).RESULTS: Fasting prolactin levels varied considerably, and mean fasting prolactin levels did not significantly differ between patients and controls (12.33, SD 11.58 vs. 10.06, SD 8.67 ng/ml, p = 0.623). In the controls, postprandial serum prolactin was significantly reduced (Δ -2.53, SD 9.75 ng/ml, p = 0.016). In antipsychotic-treated patients postprandial serum prolactin tended to increase (Δ 2.62, SD 10.96 ng/ml, p = 0.081). Analyses of subgroups based on the prolactinogenic liability of their antipsychotic treatment indicated 22 to 65% higher postprandial prolactin levels with high and intermediate prolactinogenic antipsychotics.DISCUSSION: A physiological postprandial suppression of serum prolactin appears absent in antipsychotic-treated males. Marked variability in fasting prolactin levels may reflect individual variations in the diurnal cycle. Uniform acquisition procedures accounting for diurnal variation and food intake may enhance reliability of prolactin levels in antipsychotic-treated male patients.

AB - INTRODUCTION: Hyperprolactinemia is a common side-effect of antipsychotic treatment. Antipsychotics and hyperprolactinemia are both considered risk factors of metabolic disturbances and diabetes. Investigations on prolactin response to meal ingestion in antipsychotic-treated patients are missing.MATERIAL AND METHODS: In a case-control design, 49 antipsychotic-treated, clinically stable, non-diabetic, schizophrenia spectrum male patients were compared with 93 healthy male controls by age (33.1, SD 7.4 vs. 32.9, SD 6.6 years), body mass index (26.2, SD 4.6 vs. 26.1, SD 3.9 kg/m(2)) and waist circumference (96.4, SD 13.0 vs. 96.7, SD 11.9 cm). Serum-prolactin was measured in the morning and 90 min after ingestion of a standardized liquid meal (2268 kJ).RESULTS: Fasting prolactin levels varied considerably, and mean fasting prolactin levels did not significantly differ between patients and controls (12.33, SD 11.58 vs. 10.06, SD 8.67 ng/ml, p = 0.623). In the controls, postprandial serum prolactin was significantly reduced (Δ -2.53, SD 9.75 ng/ml, p = 0.016). In antipsychotic-treated patients postprandial serum prolactin tended to increase (Δ 2.62, SD 10.96 ng/ml, p = 0.081). Analyses of subgroups based on the prolactinogenic liability of their antipsychotic treatment indicated 22 to 65% higher postprandial prolactin levels with high and intermediate prolactinogenic antipsychotics.DISCUSSION: A physiological postprandial suppression of serum prolactin appears absent in antipsychotic-treated males. Marked variability in fasting prolactin levels may reflect individual variations in the diurnal cycle. Uniform acquisition procedures accounting for diurnal variation and food intake may enhance reliability of prolactin levels in antipsychotic-treated male patients.

U2 - 10.1016/j.psyneuen.2015.05.014

DO - 10.1016/j.psyneuen.2015.05.014

M3 - Letter

C2 - 26094073

VL - 60

SP - 1

EP - 6

JO - Psychoneuroendocrinology

JF - Psychoneuroendocrinology

SN - 0306-4530

ER -

ID: 150710288